English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Article details
01 May 2020 - COVID-19 and coagulation risk, the first Italian register of patients by the scientists of the Arianna Anticoagulation Foundation is born

A great project supported by ITALFARMACO in Covid and thromboembolic complications.

In particular, learning and counteracting the lethal effects of COVID-19 on blood clotting through the study of the medical records of patients hospitalized so far in Italian hospitals.

The START-COVID initiative of the ARIANNA Anticoagulation Foundation is supported by ITALFARMACO, that has always been involved in the study, production and distribution of standard heparins and low molecular weight heparins.

The START-COVID register will allow, among other things, to retrospectively correlate the use and doses of drugs such as enoxaparin with the clinical conditions of a representative number of patients with COVID-19 and the evolution of their disease.

View the press release (PDF, Only in italian)

Statements about the START-COVID-19 register (PDF, Only in italian)

Covid-19: the stages of the disease, the body's inflammatory reaction and thrombosis (PDF, Only in italian)

Covid-19 and coagulation, the risk of thrombosis in the course of the disease (PDF, Only in italian)

What is an observational log? (PDF, Only in italian)

The importance of observational studies in the fight against Covid-19 (PDF, Only in italian)

The GHEMAVID platform of Italfarmaco (PDF, Only in italian)